ArticleHuman vaccines & immunotherapeutics2022
Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years.
J Kevin Yin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.